The first quantitative histomorphological analyses of bone vitality and inflammation in surgical specimens of patients with medication-related osteonecrosis of the jaw

被引:4
作者
Mamilos, Andreas [1 ]
Spoerl, Steffen [2 ]
Spanier, Gerrit [2 ]
Ettl, Tobias [2 ]
Brochhausen, Christoph [1 ]
Klingelhoeffer, Christoph [2 ]
机构
[1] Univ Regensburg, Dept Pathol, Regensburg, Germany
[2] Univ Hosp Regensburg, Dept Craniomaxillofacial Surg, Franz Josef Str Allee 11, D-93053 Regensburg, Germany
关键词
histopathology; inflammation; regeneration; medication-related osteonecrosis of the jaw; surgery; BISPHOSPHONATE-RELATED OSTEONECROSIS; ZOLEDRONIC ACID; RISK-FACTORS; MANAGEMENT; CANCER; DENOSUMAB;
D O I
10.1111/jop.13112
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background The purpose of the study was to categorize the vitality and inflammation of resected bone of patients with medication-related osteonecrosis of the jaw (MRONJ) and to correlate the grade of inflammation with the surgical success. Methods This prospective study includes 44 patients with stage III MRONJ. Necrotic bone was resected in a block fashioned way. After demineralization and staining, histological analyses were performed by measuring the areas of necrotic, vital, and regenerative bone. Areas of chronic and acute inflammation were categorized as non, mild, moderate, and severe and were correlated with surgical success and parameters of inflammation in blood plasma (C-reactive protein and leukocytes). Results An average area of 59.0% was necrotic in the examined specimen. Vital bone was measured with an average area of 40.9%. The stage of chronic inflammation correlated with the amount of vital bone (P < .001) and the success of surgery (P = .002). If acute inflammation was dominant, chronic inflammation areas were found less while necrotic areas were observed more (P < .001). Also, the risk of relapses, wound healing disorders, and the level of C-reactive protein were elevated if acute inflammation was severe or moderate (P = .031). Areas of bone regeneration were seen only in 11.3% of vital bone areas and occurred independently of infection stages. Conclusion If possible, surgery should be delayed in patients with signs of severe acute inflammation. Patients may profit from prolonged pre-operative antibiotic therapy to reduce the level of acute inflammation.
引用
收藏
页码:76 / 84
页数:9
相关论文
共 29 条
  • [1] Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III
    Bodem, Jens Philipp
    Schaal, Carolin
    Kargus, Steffen
    Saure, Daniel
    Mertens, Christian
    Engel, Michael
    Hoffmann, Juergen
    Freudlsperger, Christian
    [J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2016, 121 (04): : 367 - 372
  • [2] Value of nonsurgical therapeutic management of stage I bisphosphonate-related osteonecrosis of the jaw
    Bodem, Jens Philipp
    Kargus, Steffen
    Engel, Michael
    Hoffmann, Juergen
    Freudlsperger, Christian
    [J]. JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2015, 43 (07) : 1139 - 1143
  • [3] The Role of Surgical Resection in the Management of Bisphosphonate-Related Osteonecrosis of the Jaws
    Carlson, Eric R.
    Basile, John D.
    [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (05) : 85 - 95
  • [4] Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
    Fizazi, Karim
    Carducci, Michael
    Smith, Matthew
    Damiao, Ronaldo
    Brown, Janet
    Karsh, Lawrence
    Milecki, Piotr
    Shore, Neal
    Rader, Michael
    Wang, Huei
    Jiang, Qi
    Tadros, Sylvia
    Dansey, Roger
    Goessl, Carsten
    [J]. LANCET, 2011, 377 (9768) : 813 - 822
  • [5] Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading
    Follet, Helene
    Li, Jiliang
    Phipps, Roger J.
    Hui, Siu
    Condon, Keith
    Burr, David B.
    [J]. BONE, 2007, 40 (04) : 1172 - 1177
  • [6] Fournier P, 2002, CANCER RES, V62, P6538
  • [7] Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
    Gnant, Michael
    Pfeiler, Georg
    Dubsky, Peter C.
    Hubalek, Michael
    Greil, Richard
    Jakesz, Raimund
    Wette, Viktor
    Balic, Marija
    Haslbauer, Ferdinand
    Melbinger, Elisabeth
    Bjelic-Radisic, Vesna
    Artner-Matuschek, Silvia
    Fitzal, Florian
    Marth, Christian
    Sevelda, Paul
    Mlineritsch, Brigitte
    Steger, Guenther G.
    Manfreda, Diether
    Exner, Ruth
    Egle, Daniel
    Bergh, Jonas
    Kainberger, Franz
    Talbot, Susan
    Warner, Douglas
    Fesl, Christian
    Singer, Christian F.
    [J]. LANCET, 2015, 386 (9992) : 433 - 443
  • [8] Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis
    Gross, Christian
    Weber, Manuel
    Creutzburg, Kay
    Moebius, Patrick
    Preidl, Raimund
    Amann, Kerstin
    Wehrhan, Falk
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15
  • [9] Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer
    Guarneri, Valentina
    Miles, David
    Robert, Nicholas
    Dieras, Veronique
    Glaspy, John
    Smith, Ian
    Thomssen, Christoph
    Biganzoli, Laura
    Taran, Tanya
    Conte, PierFranco
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (01) : 181 - 188
  • [10] Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis
    Hansen, T
    Kunkel, M
    Weber, A
    Kirkpatrick, CJ
    [J]. JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2006, 35 (03) : 155 - 160